Paysign(NASDAQ) PAYS

PaySign helps businesses pay people using prepaid cards. It makes sending rewards or medical payments fast and simple. These services help donors, patients, and employees get paid easily.

What Does PaySign Do?

• Plasma Donor Payments: Specialized payment systems for plasma collection centers; currently used by approximately 48% of centers in the United States and Puerto Rico.
• Pharmaceutical Solutions: Patient affordability and co-pay assistance tools that help drug manufacturers manage insurance claims and prescription costs.
• Corporate Incentives: Reward programs for businesses including consumer rebates, sales commissions, and compensation for clinical trial participants.
• Life Science Software: Cloud-based technology branded as Apherion that manages operations for blood and plasma collection organizations.
• Digital Banking: Personal debit card accounts known as PaySign Premier that offer features similar to traditional bank accounts.

Moving Into New Markets

• Marketed services under the PaySign brand to expand from pharmaceutical assistance into broader corporate and government reward programs.
• Launched an open-loop gift card business at the end of 2022 to diversify its payment products.
• Introduced the Apherion software platform to provide integrated operating systems for regulated medical collection environments.
• Expanded the PaySign Premier digital bank account to reach consumers who lack traditional bank accounts.

The Secret to Their Success

PaySign operates its own proprietary platform to manage everything from card design and transaction processing to 24/7 customer service. This vertical integration allows the company to customize payment programs quickly while maintaining direct control over data and security.

A Look at the Numbers

• Revenue grew to $22.8 million in Q4 2025, up 45.8% from the previous year.
• Operating income reached $1.9 million in Q4 2025, up 299.3% year-over-year.
• Free cash flow hit $45.8 million in Q4 2025, up 284.4% from Q4 2024.
• Gross profit was $4.8 million in Q4 2025, down 47.8% year-over-year.

Bottom Line

PaySign has evolved from a niche pharmaceutical processor into a broader financial technology provider for the healthcare and corporate sectors. Its focus on specialized markets like plasma donation provides a stable foundation for its growing digital payment and software services.